205 related articles for article (PubMed ID: 31746356)
21. Discovery of [4-Amino-2-(1-methanesulfonylpiperidin-4-ylamino)pyrimidin-5-yl](2,3-difluoro-6- methoxyphenyl)methanone (R547), a potent and selective cyclin-dependent kinase inhibitor with significant in vivo antitumor activity.
Chu XJ; DePinto W; Bartkovitz D; So SS; Vu BT; Packman K; Lukacs C; Ding Q; Jiang N; Wang K; Goelzer P; Yin X; Smith MA; Higgins BX; Chen Y; Xiang Q; Moliterni J; Kaplan G; Graves B; Lovey A; Fotouhi N
J Med Chem; 2006 Nov; 49(22):6549-60. PubMed ID: 17064073
[TBL] [Abstract][Full Text] [Related]
22. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta.
Reynisdóttir I; Polyak K; Iavarone A; Massagué J
Genes Dev; 1995 Aug; 9(15):1831-45. PubMed ID: 7649471
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-dependent kinases as potential targets for colorectal cancer: past, present and future.
M Manohar S
Future Med Chem; 2022 Jul; 14(14):1087-1105. PubMed ID: 35703127
[TBL] [Abstract][Full Text] [Related]
24. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas.
Huls G; Koornstra JJ; Kleibeuker JH
Lancet; 2003 Jul; 362(9379):230-2. PubMed ID: 12885487
[TBL] [Abstract][Full Text] [Related]
25. Transforming growth factor beta 1 increases the stability of p21/WAF1/CIP1 protein and inhibits CDK2 kinase activity in human colon carcinoma FET cells.
Gong J; Ammanamanchi S; Ko TC; Brattain MG
Cancer Res; 2003 Jun; 63(12):3340-6. PubMed ID: 12810668
[TBL] [Abstract][Full Text] [Related]
26. Do Aspirin and Flavonoids Prevent Cancer through a Common Mechanism Involving Hydroxybenzoic Acids?-The Metabolite Hypothesis.
Sankaranarayanan R; Kumar DR; Patel J; Bhat GJ
Molecules; 2020 May; 25(9):. PubMed ID: 32397626
[TBL] [Abstract][Full Text] [Related]
27. Amplified CDK2 and cdc2 activities in primary colorectal carcinoma.
Kim JH; Kang MJ; Park CU; Kwak HJ; Hwang Y; Koh GY
Cancer; 1999 Feb; 85(3):546-53. PubMed ID: 10091728
[TBL] [Abstract][Full Text] [Related]
28. Effects of 5-FU and anti-EGFR antibody in combination with ASA on the spherical culture system of HCT116 and HT29 colorectal cancer cell lines.
Olejniczak-Kęder A; Szaryńska M; Wrońska A; Siedlecka-Kroplewska K; Kmieć Z
Int J Oncol; 2019 Jul; 55(1):223-242. PubMed ID: 31180528
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of cell-cycle progression in human colorectal carcinoma Lovo cells by andrographolide.
Shi MD; Lin HH; Lee YC; Chao JK; Lin RA; Chen JH
Chem Biol Interact; 2008 Aug; 174(3):201-10. PubMed ID: 18619950
[TBL] [Abstract][Full Text] [Related]
30. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine.
Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M
Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the melanoma cell cycle and regulation at the G1/S transition by 12-O-tetradecanoylphorbol-13-acetate (TPA) by modulation of CDK2 activity.
Coppock DL; Buffolino P; Kopman C; Nathanson L
Exp Cell Res; 1995 Nov; 221(1):92-102. PubMed ID: 7589260
[TBL] [Abstract][Full Text] [Related]
32. Expression of cyclins and cdks throughout murine carcinogenesis.
Yerly-Motta V; Contassot E; Pavy JJ; Tiberghien P; Hervé P
Cell Mol Biol (Noisy-le-grand); 1999 Dec; 45(8):1217-28. PubMed ID: 10643971
[TBL] [Abstract][Full Text] [Related]
33. Staurosporine-induced growth inhibition of glioma cells is accompanied by altered expression of cyclins, CDKs and CDK inhibitors.
Harmalkar MN; Shirsat NV
Neurochem Res; 2006 May; 31(5):685-92. PubMed ID: 16770740
[TBL] [Abstract][Full Text] [Related]
34. An insight into the emerging role of cyclin-dependent kinase inhibitors as potential therapeutic agents for the treatment of advanced cancers.
Chohan TA; Qayyum A; Rehman K; Tariq M; Akash MSH
Biomed Pharmacother; 2018 Nov; 107():1326-1341. PubMed ID: 30257348
[TBL] [Abstract][Full Text] [Related]
35. Animal Models for Studying the In Vivo Functions of Cell Cycle CDKs.
Risal S; Adhikari D; Liu K
Methods Mol Biol; 2016; 1336():155-66. PubMed ID: 26231715
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent kinase inhibitors for treating cancer.
Toogood PL
Med Res Rev; 2001 Nov; 21(6):487-98. PubMed ID: 11607930
[TBL] [Abstract][Full Text] [Related]
37. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.
Khan T; Seddon AM; Dalgleish AG; Khelwatty S; Ioannou N; Mudan S; Modjtahedi H
Oncol Rep; 2020 Dec; 44(6):2581-2594. PubMed ID: 33125153
[TBL] [Abstract][Full Text] [Related]
38. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
39. Cell cycle molecular targets in novel anticancer drug discovery.
Buolamwini JK
Curr Pharm Des; 2000 Mar; 6(4):379-92. PubMed ID: 10788588
[TBL] [Abstract][Full Text] [Related]
40. Reduction of Cdc25A contributes to cyclin E1-Cdk2 inhibition at senescence in human mammary epithelial cells.
Sandhu C; Donovan J; Bhattacharya N; Stampfer M; Worland P; Slingerland J
Oncogene; 2000 Nov; 19(47):5314-23. PubMed ID: 11103932
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
